Viability assessment by delayed enhancement cardiovascular magnetic resonance: will low-dose dobutamine dull the shine?
Kim
Raymond J
RJ
Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center, Durham, NC 27710, USA. Raymond.Kim@dcmrc.mc.duke.edu
Manning
Warren J
WJ
D000818:Animals; D019540:Area Under Curve; D002316:Cardiotonic Agents / Q000008:administration & dosage; D002470:Cell Survival; D002921:Cicatrix / Q000473:pathology; D004280:Dobutamine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D019028:Magnetic Resonance Imaging, Cine; D023421:Models, Animal; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000473:pathology* / Q000628:therapy; D009204:Myocardial Revascularization; D009206:Myocardium / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000473:pathology; D012372:ROC Curve; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon
D002316:Cardiotonic Agents; D004280:Dobutamine